Relationship Between Metabolic DysfunctionAssociated Steatotic Liver Disease and Lipoprotein (a) and Other Biomarkers

被引:0
|
作者
Rossi, Felipe A. Munoz [1 ]
Agudelo, Juanita Salazar [2 ]
Castro, Nestor Israel Quinapanta [3 ]
Mosquera, Sofia Z. [2 ]
Fajardo, Maria Clara Mejia [4 ]
Lopez, Edgar Dario Mosquera [5 ]
Olarte, Jonathan Dany Espitia [1 ]
Medina, Maria Andrea Figueroa [6 ]
Simancas, Edwin Zuniga [7 ]
Osuna, Luis Fernando Saldarriaga [8 ]
机构
[1] Univ Nacl Colombia, Internal Med, Bogota, Colombia
[2] CES Clin, Emergency Med, Medellin, Colombia
[3] Reg Autonomous Univ Andes, Res & Biostat, Ambato, Ecuador
[4] Cooperat Univ Colombia, Gen Med, Medellin, Colombia
[5] Univ Cent Ecuador, Gen Med, Quito, Ecuador
[6] Libre Univ Colombia, Gen Med, Barranquilla, Colombia
[7] Sinu Univ, Cardiovasc & Metab Ctr, Gen Clin Caribbean, Blas Lezo Clin,Internal Med, Cartagena, Colombia
[8] Univ Nacl Colombia, Bogota, Colombia
关键词
non-alcoholic fatty liver disease; gamma glutamyl transferase (ggt); nash and steatosis; high-density lipoproteins (hdl-c); lipoprotein (a); INSULIN-RESISTANCE; RISK; STEATOHEPATITIS; EPIDEMIOLOGY; ASSOCIATION;
D O I
10.7759/cureus.63019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Metabolic dysfunction -associated steatotic liver disease (MASLD) primarily affects the adult population and is closely related to obesity. The most severe form of MASLD, metabolic dysfunctionassociated steatohepatitis (MASH), can progress to liver fibrosis. While lipoprotein(a) (Lp(a)) is known to be associated with cardiovascular disease, its relationship with MASLD remains unclear. This study aims to determine the prevalence of MASLD in ambulatory patients and to explore the association between Lp(a) levels and advanced liver damage. Methods: This retrospective cross-sectional study included 130 patients older than 18 years seen in a healthcare center in Medellin, Colombia, between April 2023 and May 2024. Sociodemographic, clinical, and specific biomarker data were collected. Patients with cirrhosis, previous liver disease, frequent alcohol consumption, cancer, and other severe conditions were excluded. Continuous variables were analyzed using Student's t -tests or Mann -Whitney tests according to their distribution, and categorical variables were analyzed using contingency tables and chi-square tests. Results: Of the 130 patients, 57.9% (n=73) had MASLD, with a higher prevalence in patients with obesity (80%, n=32). Lp(a) levels were abnormally high in 43.1% (n=31) of patients; however, a weak but significant inverse correlation was found between Lp(a) levels and the Fibrosis -4 (FIB -4) score, which is used to assess the severity of liver fibrosis. Patients with MASLD had significantly lower high -density lipoprotein (HDL) and vitamin D levels, and higher levels of gamma-glutamyl transferase (GGT). Conclusions: This study highlights the significant prevalence of MASLD in outpatients and its relationship with various biomarkers, including Lp(a), HDL, vitamin D, and GGT. Although the findings suggest a possible utility of Lp(a) as a biomarker in MASLD, longitudinal studies are needed to confirm these associations and clarify their role in liver disease progression. The study's limitations include its cross-sectional nature and potential selection bias, indicating the need for further research to validate these results.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases
    Zhong, Qi
    Zhou, Rui
    Huang, Yi-Ning
    Huang, Rui-Dian
    Li, Fu-Rong
    Chen, Hao-Wen
    Wei, Yan-Fei
    Liu, Kuan
    Cao, Bi-Fei
    Liao, Kai-Yue
    Xu, Zheng-Yun
    Wang, Shi-Ao
    Wu, Xian-Bo
    JOURNAL OF HEPATOLOGY, 2025, 82 (03)
  • [22] Applying proteomics in metabolic dysfunction-associated steatotic liver disease: From mechanism to biomarkers
    Zhang, Xiaofu
    Li, Xiaoying
    Xiong, Xuelian
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2023, 47 (10)
  • [23] THE LIPIDOMIC PROFILE DISCRIMINATES BETWEEN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AND COMBINED METABOLIC DYSFUNCTION- AND ALCOHOL-RELATED STEATOTIC LIVER DISEASE
    Schneider, Carolin Victoria
    Loomba, Rohit
    Huang, Helen
    Raptis, Anastasia
    Creasy, Kate Townsend
    Clusmann, Jan
    Van Haag, Felix
    Luedde, Tom
    Francque, Sven
    Schneider, Kai Markus
    HEPATOLOGY, 2024, 80 : S453 - S454
  • [24] Relationship between anthropometric measures and the risk of incident Metabolic dysfunction-associated steatotic liver disease: a longitudinal study
    Takahiro Ichikawa
    Yoshitaka Hashimoto
    Takuro Okamura
    Akihiro Obora
    Takao Kojima
    Hiroshi Okada
    Masahide Hamaguchi
    Michiaki Fukui
    BMC Gastroenterology, 25 (1)
  • [25] Causal relationship between depression and metabolic dysfunction-associated steatotic liver disease: a bidirectional Mendelian randomized study
    Liang, Weiyu
    Zhong, Kunting
    Lai, Tingting
    Zeng, Yuhao
    Huang, Zhanhui
    Zhou, Jiqing
    Huang, Jin
    Shi, Zhenni
    Zhang, Jin
    Ding, Fuping
    FRONTIERS IN PSYCHIATRY, 2024, 15
  • [26] IMPACT OF ANTHROPOMETRIC PARAMETERS ON OUTCOMES IN ASIANS WITH METABOLIC DYSFUNCTIONASSOCIATED FATTY LIVER DISEASE
    Ha, Yeonjung
    Chon, Young Eun
    Lee, Joo Ho
    Lee, Kwan Sik
    HEPATOLOGY, 2023, 78 : S977 - S977
  • [27] Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
    Loomba, Rohit
    Wong, Vincent Wai-Sun
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 150 - 156
  • [28] Non-metabolic causes of steatotic liver disease
    Nasr, Patrik
    Jonsson, Cecilia
    Ekstedt, Mattias
    Kechagias, Stergios
    METABOLISM AND TARGET ORGAN DAMAGE, 2023, 3 (04):
  • [29] Association between longitudinal biomarkers and major adverse liver outcomes in patients with non-cirrhotic metabolic dysfunction-associated steatotic liver disease
    Shang, Ying
    Akbari, Camilla
    Dodd, Maja
    Zhang, Xiao
    Wang, Tongtong
    Jemielita, Thomas
    Fernandes, Gail
    Engel, Samuel S.
    Nasr, Patrik
    Vessby, Johan
    Rorsman, Fredrik
    Kechagias, Stergios
    Stal, Per
    Ekstedt, Mattias
    Hagstrom, Hannes
    HEPATOLOGY, 2024,
  • [30] Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
    Staufer, Katharina
    Stauber, Rudolf E.
    BIOMEDICINES, 2023, 11 (08)